Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: A situational analysis

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 7, 2010, Pages 884-889

  He, Guan Xue ^a,b   Van Den Hof, S ^b,c   Borgdorff, M W ^b   Van Der Werf, M J ^b,c   Cheng, S M ^a   Hu, Y L ^a   Zhang, L X ^d   Wang, L X ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug resistance; MDR TB; Second line drugs; Tuberculosis; XDR TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT; QUINOLONE DERIVATIVE;

ARTICLE; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG SENSITIVITY; DRUG USE; HEALTH CARE FACILITY; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QUALITY CONTROL; SPUTUM CULTURE; TREATMENT INDICATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; HEALTH CARE SURVEY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SPUTUM; SUPPLY AND DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CHINA; CROSS-SECTIONAL STUDIES; FLUOROQUINOLONES; HEALTH CARE SURVEYS; HUMANS; MICROBIAL SENSITIVITY TESTS; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77953629601     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The Beijing 'call for action' on tuberculosis control and patient care: together addressing the global M/XDR-TB epidemic. A ministerial meeting of high M/XDR-TB burden countries, 1-3 April 2009. Beijing, China: WHO, 2009. http://www.who.int/tb-beijingmeeting/media/en-call-for-action.pdf Accessed April 2010.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland. WHO, 2008.
3. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55: 1176.
4. Shah N S, Wright A, Bai G H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
5. Sun Z, Chao Y, Zhang X, et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol 2008; 46: 4075-4077.
6. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-1873.
7. Cheng M H. Ministerial meeting agrees plan for tuberculosis control. Lancet 2009; 373: 1328.
8. Gao W, Zhao Y, Liu Y, et al. Clinical analysis of 104 multidrug resistance pulmonary tuberculosis of different patterns. J Chinese Anti-tuberculosis Assoc 2008; 30: 114-117. [Chinese]
9. Mitnick C D, McGee B, Peloquin C A. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10: 381-401.
10. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-439.
11. Wang J Y, Lee L N, Lai H C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-865.
12. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to CFX and ofl oxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
13. von Gottberg A, Klugman K P, Cohen C, et al. Emergence of levofl oxacin-non-susceptible Streptococcus and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008; 371: 1108-1113.
14. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
15. Tan W, Deng W, Zhao M, et al. Evaluation on management and treatment of MDR-TB patients in Shenzhen. J Chinese Anti-Tuberculosis Assoc 2008; 31: 256-258. [Chinese]
16. Wang K, Gu J, Tang S. Treatment results for 50 cases of MDRTB. J Chinese Anti-Tuberculosis Assoc 2008; 31: 301-302. [Chinese]
17. Zhang G, Du C, Kurasawa T, et al. China-Japan cooperation project on second-line tuberculosis drug resistance survey in Henan Province. J Med Forum 2005; 26: 14-16.
18. Kam K M, Yip C W. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis 2004; 8: 760-766.
19. Espinal M, Raviglione M C. From threat to reality: the real face of multi-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 216-217.